You are here » Home » Companies » Company Overview » Metropolis Healthcare Ltd

Metropolis Healthcare Ltd.

BSE: 542650 Sector: Health care
NSE: METROPOLIS ISIN Code: INE112L01020
BSE 00:00 | 22 Sep 2998.85 -71.85
(-2.34%)
OPEN

3083.15

HIGH

3099.95

LOW

2973.95

NSE 00:00 | 22 Sep 3000.70 -69.85
(-2.27%)
OPEN

3081.70

HIGH

3081.90

LOW

2974.00

OPEN 3083.15
PREVIOUS CLOSE 3070.70
VOLUME 10340
52-Week high 3240.95
52-Week low 1687.25
P/E 63.07
Mkt Cap.(Rs cr) 15,339
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 3083.15
CLOSE 3070.70
VOLUME 10340
52-Week high 3240.95
52-Week low 1687.25
P/E 63.07
Mkt Cap.(Rs cr) 15,339
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Metropolis Healthcare Ltd. (METROPOLIS) - Company History

Dr. Sushil Kanubhai Shah one of the Promoters commenced pathology business in January 1980 as a partnership firm in the name of Dr. V. K. Desai's Hospital having Dr. Kanubhai M. Shah Dr. Sushil Kanubhai Shah and Dr. Vasant Kalyandas Desai as partners. The partnership was continued by Dr. Sushil Kanubhai Shah Dr. Kanubhai M. Shah and Dr. Duru Sushil Shah from September 30 1981 onwards. In June 1989 upon death of Dr. Kanubhai M. Shah the partnership was continued by Dr. Sushil Kanubhai Shah and Dr. Duru Sushil Shah. Prior to March 18 1995 Dr. Sushil Kanubhai Shah was also carrying on a business of radioimmunoassay and pathology laboratory on a sole proprietorship basis. On March 20 1995 the said sole proprietorship business was converted into a partnership with Dr. Sushil Kanubhai Shah Dr. Duru Sushil Shah and Aparna S. Shah (Rajadhyaksha) as partners in the name and style of Metropolis Lab. In January 1998 Ameera Sushil Shah was inducted as an additional partner in Metropolis Lab. With effect from February 1 2002 the business of Metropolis Lab was transferred to Dr. V. K. Desai's Hospital as a going concern. In May 2002 Dr. G. S. K. Velu and Subbulakshmi K. Velu were admitted as partners in Dr. V. K. Desai Hospitals. The name of Dr. V. K. Desai's Hospital was changed to Metropolis Health Services in November 2002. Further in April 2003 Ameera Sushil Shah Jaswanti Kanubhai Shah Sadacharan Gomanthybabu and Gomathybabu Gomathy were admitted as partners in Metropolis Health Services. In July 2003 Metropolis Health Services was converted into a private limited company as Metropolis Health Services (India) Private Limited ('MHSIPL'). The name of MHSIPL was changed to Metropolis Health Services (India) Limited ('MHSIL') pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' on March 1 2006. In January 2009 MHSIL amalgamated with Pathnet India Private Limited which was a wholly owned subsidiary of MHSIL. Pathnet India Private Limited was incorporated at New Delhi as a private limited company on November 10 2000. The name of the Company was changed to Pathnet India Limited pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name on Conversion to Public Limited Company' on July 1 2009. The name of the Company was changed to Metropolis Healthcare Limited pursuant to a Fresh Certificate of Incorporation Consequent upon Change of Name' granted by RoC on September 23 2009. Metropolis Healthcare is one of the leading diagnostics companies in India. It has widespread presence across 19 states in India with leadership position in west and south India. Through its widespread operational network it offers a comprehensive range of clinical laboratory tests and profiles which are used for prediction early detection diagnostic screening confirmation and/or monitoring of the disease. It also offers analytical and support services to clinical research organizations for their clinical research projects.The Company conducts its operations through their laboratory and service network. It has implemented a hub and spoke' model for quick and efficient delivery of services through their widespread laboratory and service network which covers 197 cities in India. As of December 31 2018 its laboratory network consists of 115 clinical laboratories comprising (i) a global reference laboratory ('GRL') located in Mumbai which is the main hub' and equipped to conduct majority of the tests offered by them; (ii) 14 regional reference laboratories ('RRLs') (out of which four are located outside India) which are equipped to conduct routine semi-specialized and few specialized tests; (iii) 56 satellite laboratories (out of which one is located outside India) which are equipped to conduct routine and semi-specialized tests; and (iv) 44 express laboratories (out of which five are located outside India) which are equipped to conduct routine tests. Metropolis Healthcare has been awarded the tender by the National Aids Control Organization ('NACO') to collect specimens from 525 government-owned antiretroviral therapy (ART) centers and conduct HIV-1-Viral load tests. It also offers analytical services and support services such as logistics and electronic data interchange ('EDI') to contract research organizations for their clinical research projects. Outside India it has laboratory operations in Ghana Kenya Zambia Mauritius and Sri Lanka. In addition it has also entered into agreements with third parties for collection and processing of specimens in Nepal Nigeria UAE and Oman. Metropolis' brand is recognized for delivering quality diagnostic and related healthcare tests and services. For instance it received 'excellence in customer service and delivery' award from Biotrains in 2018 and also received special jury mention for 'service excellence (diagnostic center)' by FICCI at the Healthcare Excellence Awards 2018. In addition its health campaign was recognized as 'best in health and fitness' in the Digital Campaign Awards 2018 by LH Insights.Metropolis Healthcare Ltd. came out with an Initial Public Offering (IPO) of 13685095 equity shares of Face Value of Rs 2/- each of the company for cash at a price of Rs 880 per equity share aggregating Rs 1204.29 Crores consisting of an offer for sale of 6272335 equity shares by Dr. Sushil Kanubhai Shah (the promoter selling shareholder) aggregating to 551.97 Crores and 7412760 equity shares by Ca Lotus Investments (the investor selling shareholder) aggregating 652.32 Crores. The face value of equity shares is Rs 2/-each. The IPO was priced at Rs 880 per equity share.

.